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ABSTRACT 
Controlled release (CR) dosage forms have been extensively used to improve therapy with many important drugs. Several approaches are currently utilized in prolongation of 
gastric residence time, including floating drug delivery system, swelling and expanding system, polymeric bioadhesive system, modified shape system, high density system and 
other delayed gastric emptying devices. However, the development processes are faced with several physiological difficulties such as the inability to restrain and localize the 
system within the desired region of the gastrointestinal tract and the highly variable nature of the gastric emptying process. On the other hand, incorporation of the drug in a 
controlled release gastroretentive dosage forms (CR-GRDF) which can remain in the gastric region for several hours would significantly prolong the gastric residence time of 
drugs and improve bioavailability, reduce drug waste, and enhance the solubility of drugs that are less soluble in high pH environment. Gastroretention would also facilitate 
local drug delivery to the stomach and proximal small intestine. Thus, gastroretention could help to provide greater availability of new products and consequently improved 
therapeutic  activity  and  substantial  benefits  to  patients.  The  purpose  of  this  paper  is  to  review  the  recent  literature  and  current  technology  used  in  the  development  of 
gastroretentive dosage forms. 
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INTRODUCTION 
Gastric emptying of dosage forms is an extremely variable process 
and ability to prolong and control the emptying time is a valuable 
asset for dosage  forms, which reside in the stomach for a longer 
period of time than conventional dosage forms. Several difficulties 
are  faced  in  designing  controlled  release  systems  for  better 
absorption and enhanced bioavailability. One of such difficulties is 
the inability to confine the dosage form in the desired area of the 
gastrointestinal tract. Drug absorption from the gastrointestinal tract 
is a complex procedure and is subject to many variables. It is widely 
acknowledged  that  the  extent  of  gastrointestinal  tract  drug 
absorption  is  related  to  contact  time  with  the  small  intestinal 
mucosa.
1  Thus;  small  intestinal  transit  time  is  an  important 
parameter for drugs that are incompletely absorbed. Basic human 
physiology  with the details of gastric emptying, motility  patterns, 
and  physiological  and  formulation  variables  affecting  the  cosmic 
emptying are summarized. GRFDDS has also applications for local 
drug delivery to the stomach and proximal small intestines. Gastro 
retention helps to provide better availability of new products with 
new therapeutic possibilities and substantial benefits for patients
2. 
Basic Gastrointestinal Tract Physiology 
Anatomically the stomach is divided into 3 regions: fundus, body, 
and antrum (pylorus). The proximal part made of fundus and body 
acts as a reservoir for undigested material, whereas the antrum is the 
main site for mixing motions and act as a pump for gastric emptying 
by  propelling  actions
3.  Gastric  emptying  occurs  during  fasting  as 
well as fed states. The pattern of motility is however distinct in the 2 
states. 
During the fasting state an interdigestive series of electrical events 
take place, which cycle both through stomach and intestine every 2 
to  3 hours. This  is  called the  interdigestive  myloelectric cycle  or 
migrating myloelectric cycle (MMC), which is further divided into 
following  4  phases  as  described  by  Wilson  and  Washington
4. 
(Figure 1) 
Phase  I  (basal  phase)  lasts  from  30  to  60  minutes  with  rare 
contractions. 
Phase II (preburst phase) lasts for 20 to 40 minutes with intermittent 
action potential and contractions. In this phase bile secretion takes 
place.  As  the  phase  progresses  the  intensity  and  frequency  also 
increases gradually. 
Phase III (burst phase) lasts for 10 to 20 minutes. It includes intense 
and regular contractions for short period. It is due to this wave that 
all the undigested material and mucus is swept out of the stomach 
down  to  the  small  intestine.  It is  also  known  as  the housekeeper 
wave. 
Phase IV lasts for 0 to 5 minutes and occurs between phases III and 
I of 2 consecutive cycles. 
After  the  ingestion  of  a  mixed  meal,  the  pattern  of  contractions 
changes  from  fasted  to  that  of  fed  state.  This  is  also  known  as 
digestive motility pattern and comprises continuous contractions as 
in phase II of fasted state.  
Scintigraphic  studies  determining  gastric  emptying  rates  revealed 
that  orally  administered  controlled  release  dosage  forms  are 
subjected to basically 2 complications, that of short gastric residence 
time and unpredictable gastric emptying rate.
5 
Factors Affecting Gastric Retention: Gastric residence time of an 
oral dosage form is affected by several factors. To pass through the 
pyloric valve into the small intestine the particle size should be in 
the range of 1 to 2 mm
6
. The rate of gastric emptying and gastric 
retention of GRFDDS depends mainly on- 
A) Meals: The rate of gastric emptying depends mainly on nature of 
meal and caloric content of meals. 
Nature of meal: Feeding of indigestible polymers or fatty acid salts 
can change the motility pattern of the stomach to a fed state, thus 
decreasing the gastric emptying rate and prolonging drug release. 
Caloric content of meal: GRT can be increased by four to 10 hours 
with a meal that is high in proteins and fats 
B) Volume of GI fluid: The resting volume of the stomach is 25 to 
50 mL. When volume is large, the emptying is faster. Fluids taken at 
body temperature leave the stomach faster than colder or warmer 
fluids. 
C) Dosage form related factors 
·  Density: A buoyant dosage form having a density of less than 
that of the gastric fluids floats. Since it is away from the pyloric 
sphincter,  the  dosage  unit  is  retained  in  the  stomach  for  a 
prolonged period. 
·  Size: Dosage form units with a diameter of more than 7.5mm are 
reported to have an increase GRT compared with those with a 
diameter of 9.9mm. Small-size tablets leave the stomach during Kadam Shashikant M et al / IJRAP 2011, 2 (6) 1752-1755 
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the  digestive  phase  while  the  large-size  tablets  are  emptied 
during the housekeeping waves. 
·  Shape  of  dosage  form:  Tetrahedron  and  ringshaped  devices 
with a flexural modulus of 48 and 22.5 kilopounds per square 
inch  (KSI)  are  reported  to  have  better  GRT  ≈90%  to  100% 
retention at 24 hours compared with other shapes. 
·  Single or multiple unit formulation: Multiple unit formulations 
show  a  more  predictable  release  profile  and  insignificant 
impairing  of  performance  due  to  failure  of  units,  allow  co-
administration  of  units  with  different  release  profiles  or 
containing incompatible substances and permit a larger margin of 
safety  against  dosage  form  failure  compared  with  single  unit 
dosage forms. 
D) Fed Conditions 
·  Fed or unfed state: Under fasting conditions, the GI motility is 
characterised by periods of strong motor activity or the migrating 
myoelectric complex (MMC) that occurs every 1.5 to 2 hours. 
However,  in  the  fed  state,  MMC  is  delayed  and  GRT  is 
considerably longer. 
·  Frequency of feed: The GRT can increase by over 400 minutes 
when successive meals are given compared with a single meal 
due to the low frequency of MMC. 
E) Patient related factors 
·  Gender: Mean ambulatory GRT in males (3.4±0.6 hours) is less 
compared  with  their  age and racematched  female  counterparts 
(4.6±1.2  hours),  regardless  of  the  weight,  height  and  body 
surface. 
·  Age:  Elderly  people,  especially  those  over  70,  have  a 
significantly longer GRT. 
·  Posture: GRT can vary between supine and upright ambulatory 
states of the patient. 
·  Concomitant  drug  administration:  Anticholinergics  like 
atropine and propantheline, opiates like codeine and prokinetic 
agents like metoclopramide and cisapride. 
F) Biological factors: Diabetes and Crohn’s disease, etc
7. 
Current Approaches To Gastroretentive Drug Delivery System 
A) Floating drug delivery systems (FDDS): Floating FDDS is an 
effective technology to prolong the gastric residence time in order to 
improve  the  bioavailability  of  the  drug.  FDDS  are  low-density 
systems  that  have  sufficient  buoyancy  to  float  over  the  gastric 
contents and remain in the stomach for a prolonged period
8. Floating 
systems  can  be  classified  as  effervescent  and  noneffervescent 
system. 
I) Effervescent systems 
These  buoyant  delivery  systems  utilize  matrices  prepared  with 
swellable  polymers  such  as  Methocel  or  polysaccharides,  e.g., 
chitosan, and effervescent components, e.g., sodium bicarbonate and 
citric or tartaric acid or matrices containing chambers of liquid that 
gasify at body temperature.  
Gas can be introduced into the floating chamber by the volatilization 
of an organic solvent (e.g., ether or cyclopentane) or by the carbon 
dioxide  produced  as  a  result  of  an  effervescent  reaction between 
organic  acids  and  carbonate–bicarbonate  salts  (Figure  2).  The 
matrices are fabricated so that upon arrival in the stomach, carbon 
dioxide  is  liberated  by  the  acidity  of  the  gastric  contents  and  is 
entrapped  in the  gellified  hydrocolloid.  This  produces  an  upward 
motion of the dosage form and maintains its buoyancy. Recently a 
multiple-unit type of floating pill, which generates carbon dioxide 
gas, has been developed
8. 
II) Noneffervescent systems 
Noneffervescent systems incorporate a high level (20–75% w/w) of 
one or more gel-forming, highly swellable, cellulosic hydrocolloids 
(e.g.,  hydroxyethyl  cellulose,  hydroxypropyl  cellulose, 
hydroxypropyl  methylcellulose[HPMC],  and  sodium 
carboxymethylcellulose),  polysaccharides,  or  matrix-forming 
polymers (e.g., polycarbophil, polyacrylates, and polystyrene) into 
tablets or capsules
9. Upon coming into contact with gastric fluid, 
these gel formers, polysaccharides, and polymers hydrate and form a 
colloidal gel barrier that controls the rate of fluid penetration into the 
device  and  consequent  drug  release
10-11.  The  air  trapped  by  the 
swollen polymer lowers the density of and confers buoyancy to the 
dosage form. 
B) Bio Mucoadhesive systems 
Bio mucoadhesive systems bind to the gastric epithelial cell surface, 
or  mucin,  and  increase  the  GRT  by  increasing  the  intimacy  and 
duration  of  contact  between  the  dosage  form  and  the  biological 
membrane. The adherence of the delivery system to the gastric wall 
increases  residence  time  at  a  particular  site,  thereby  improving 
bioavailability
12.  A  bio  mucoadhesive  substance  is  a  natural  or 
synthetic polymer capable of adhering to a biological membrane or 
the mucus lining of the GIT (mucoadhesive polymer). On the basis 
of  binding  of  polymers  to  the  mucin-epithelial  surface  can  be 
subdivided into two broad categories
13. 
a. Hydration-mediated adhesion 
Certain hydrophilic polymers tend to imbibe large amount of water 
and become sticky, thereby acquiring bioadhesive properties
14. 
b. Bonding-mediated adhesion 
The  adhesion  of  polymers  to  a  mucus  or  epithelial  cell  surface 
involves  various  bonding  mechanisms,  including  physical-
mechanical bonding and chemical bonding. Chemical bonds may be 
either covalent (primary) or ionic (secondary) in nature. Secondary 
chemical bonds consist of dispersive interactions (i.e., Vander Waals 
interactions)  and  stronger  specific  interactions  such  as  hydrogen 
bonds.  The hydrophilic  functional  groups responsible  for forming 
hydrogen bonds are the hydroxyl and carboxylic groups
14.   
C) Receptor-mediated adhesion 
Certain polymers can bind to specific receptor sites on the surface of 
cells,  thereby  enhancing  the  gastric  retention  of  dosage  forms. 
Certain plant lectins such as tomato lectins interact specifically with 
the sugar groups present in mucus or on the glycocalyx
14. 
D) Expandable, unfoldable and swellable Systems 
Gastroretentivity of a pharmaceutical dosage form can be enhanced 
by increasing its size above the diameter of the pylorus (Figure 3). If 
the  dosage  form  can  attain  the  larger  size  than  pylorus,  the 
gastroretentivity of that dosage form will be possible for long time. 
This large size should be achieved fairly quickly; otherwise dosage 
form  will  be  emptied  through  the  pylorus.  Thus,  configurations 
required to develop an expandable system to prolong GRT are: 
I. a small configuration for oral intake, 
ii. An expanded gastroretentive form, and 
iii. A final small form enabling evacuation following drug release 
from the device. 
In addition they should be able enough to withstand peristalsis and 
mechanical contractility of the stomach
14. 
However, owing to significant individual variation, the cut-off size 
cannot be determined exactly. Unfoldable systems are available in 
various shapes as shown in figure-4.The concept is to make a carrier, 
such as a capsule, which extends in the stomach. Caldwell et al, 
proposed different geometric forms like tetrahedron
15, ring or planar 
membrane  (4-lobed,  disc  or  4-limbed  cross  form)  of  bioerodible 
polymer compressed within a capsule
16.  
E) High-density systems 
Gastric contents have a density close to water (¨1.004 g/cm3). When 
high density pellets is given to the patient, it will sink to the bottom 
of the stomach and are entrapped in the folds  of the antrum and 
withstand the peristaltic waves of the stomach wall
17. Sedimentation 
has  been  employed  as  a  retention  mechanism  for  high  density 
systems.  A  density  ~3g/cm3  seems  necessary  for  significant 
prolongation of gastric residence time. Barium sulphate, zinc oxide, Kadam Shashikant M et al / IJRAP 2011, 2 (6) 1752-1755 
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iron powder, titanium dioxide may be used to formulate such high 
density systems due to their high density. The only major drawbacks 
with this  systems  is  that it  is technically  difficult  to  manufacture 
them  with  a  large  amount  of  drug  (>50%)  and  to  achieve  the 
required density of 2.4–2.8 g/cm
3. 
F) Magnetic systems 
This approach to enhance the GRT is based on the simple principle 
that the dosage form contains a small internal magnet, and a magnet 
placed on the abdomen over the position of the stomach. Ito et al, 
used  the  technological  approaches  in  rabbits  with  bioadhesive 
granules containing ultra-fine ferrite (ã-Fe2O3). They guided them 
to oesophagus with an external magnet (~1700G) for the initial 2 
minutes and almost all the granules were retained in the region after 
2 hours
18. 
G) Raft systems 
Raft  systems  incorporate  alginate  gels  these  have  a  carbonate 
component and, upon reaction with gastric acid, bubbles form in the 
gel, enabling floating
19. 
H) Super porous hydrogel systems  
Recent  developments  include  use  of  super  porous  hydrogels  that 
expand  dramatically  (hundreds  of  times  their  dehydrated  form 
within a matter of seconds) when immersed in water. With pore size 
ranging,  10  nm  to  10  μm,  absorption  window  by  conventional 
hydrogel is a very slow process and several hours may be needed to 
reach an equilibrium state during which, parameter evacuation of the 
dosage form may occur
20. Super porous hydrogels, average pore size 
less than 100 μm, swell to equilibrium size within a minute, due to 
rapid  water  uptake  by  capillary  wetting  through  numerous 
interconnected open pores
21. 
Drugs reported to be used in the formulation of FDDS 
Local treatment of the GI wall or targeting the intestine mucosa is 
aimed. GRDF is the formulation of choice when the drug is mainly 
absorbed  in  the  upper  GI  tract  and  a  reduction  of  plasma  level 
fluctuations  is  required  to  minimize  concentration-dependant 
adverse drug reactions
22. A good example for such drug is given in 
table No 3. 
Polymers and Ingredients to be used in the formulation of FDDS 
Following  types  of  ingredients  can  be  incorporated  into  HBS 
(hydrodynamically balanced system) dosage form in addition to the 
drugs: 
·  Hydrocolloids  (20%-75%): They  can  be  synthetics,  anionic  or 
non-ionic like hydrophilic gums, modified cellulose derivatives. 
E.g. Acacia, pectin, Chitosan, Agar, Casein, Bentonite, veegum, 
HPMC  (K4M,  K100M  and  K15M),  Gellan  gum  (Gelrite), 
Sodium CMC, MC, HPC. 
·  Inert  fatty  materials(5%-75%):  Edible,  inert  fatty  materials 
having a specific gravity of less than one can be used to decrease 
the  hydrophilic  property  of  formulation  and  hence  increase 
buoyancy. Eg. Beeswax, fatty acids, long chain fatty alcohols, 
Gelucires 39/01 and 43/01. 
·  Effervescent  agents:  Sodium  bicarbonate,  citric  acid,  tartaric 
acid,  Di-SGC  (Di-Sodium  Glycine  Carbonate,  CG 
(Citroglycine). Release rate accelerants (5%-60%): e.g. lactose, 
mannitol.  Release  rate  retardants  (5%-60%):  e.g.  Dicalcium 
phosphate, talc, magnesium stearate. Buoyancy increasing agents 
(upto80%):  e.g.  Ethyl  cellulose.  Low  density  material: 
Polypropylene foam powder
23. 
Advantages of Gastro retentive Drug delivery system 
Enhanced bioavailability 
The  bioavailability  of  therapeutic  agents  can  be  significantly 
enhanced especially for those which get metabolized in the upper 
GIT by gastroretentive drug delivery approaches in comparison to 
the administration of non-gastroretentive drug delivery
24. 
 
Sustained drug delivery 
HBS or bioadhesive or expandable systems type dosage forms can 
remain in the stomach for several hours and therefore, significantly 
prolong the GRT of numerous drugs.  
Site specific drug delivery 
This site-specific drug delivery reduces undesirable effects. Hence 
they are useful in the treatment of disorders related to stomach and 
small intestine (e.g. eradication of Helicobacter pylori). 
Reduced fluctuation of drug concentrations 
Continuous  input  of  the  drug  following  controlled  release 
gastroretentive  delivery  produces  systemic  drug  concentrations 
within  a  narrower  range  compared  to  the  immediate  release  oral 
dosage forms.  
Improved selectivity in receptor activation 
The  controlled  release  mode  of  drug  administration  of 
gastroretentive  systems  have  the  important  feature  that  have  an 
impact  on  the  magnitude  of  the  pharmacologic  response,  which 
minimizes  fluctuation  in  blood  drug  concentrations  (i.e.  between 
peak and trough).  
Limitations Gastro Retentive Drug Delivery System 
·  The residence time in the stomach depends upon the digestive 
state. Hence, FDDS should be administered after the meal
25
.  
·  The ability to float relies on the hydration state of the dosage 
form. In order to keep these tablets floating in vivo, intermittent 
administration  of  water  (a  tumbler  full,  every  2  hours)  is 
beneficial
25
.  
·  The ability of drug to remain in the stomach depends upon the 
subject being positioned upright
26
.  
·  FDDS  are  not  suitable  for  the  drugs  that  have  solubility  or 
stability problems in the gastric fluid
27
.  
·  Drugs like nifedipine, which is well absorbed along the entire 
GIT and which undergoes significant first pass metabolism, may 
not  be  desirable  candidates  for  FDDS  since  the  slow  gastric 
emptying may lead to the reduced systemic bio-availability
27
.  
Marketed Preparations And Some Patents On Gastroretentive 
Drug Delivery System 
Some  marketed  preparations  and  patents  on  gastroretentive  drug 
delivery system are listed in table 2 and table 3. 
DISCUSSION 
Controlled release gastroretentive dosage forms (CR-GRDF) enable 
prolonged and continuous input of the drug to the upper parts of the 
gastrointestinal tract and improve the bioavailability of medications 
that are characterized by a narrow absorption window. CR-GRDF 
provides  a  means  to  utilize  all  the  pharmacokinetic  and 
pharmacodynamic advantages of controlled release dosage forms for 
such  drugs.  Due  to  the  complexity  of  pharmacokinetic  and 
pharmacodynamic  parameters,  in  vivo  studies  are  required  to 
establish the optimal dosage form for a specific drug. For a certain 
drug,  interplay  of  its  pharmacokinetic  and  pharmacodynamic 
parameters will determine the effectiveness and benefits of the CR-
GRDF compared to the other dosage forms. 
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Table 1: Examples of drugs used in floating formulation
22 
Floating microspheres  Diclofenac sodium and prednisolone. 
Floating granules  Indomethacin and prednisolone. 
Floating tablets and 
pills 
Acetaminophen, acetylsalicylic acid, ampicillin, 
amoxicillin Trihydrate, atenolol, diltiazem. 
Floating capsules  Chlordiazepoxide hydrogen chloride, diazepam, 
furosemide, misoprostol, L-Dopa, benserazide, 
ursodeoxycholic acid, pepstatin. 
Films  Albendazole, Cinnarizine. 
 
Table 2: Marketed preparations of gastroretentive drug delivery system 
Sr.No.  Product  Active ingredient  Remark  Reference 
1  Cifran OD  Ciprofloxacine  Gas generating 
Floating Tablet 
Chawla et 
al,2004 
2  Cytotec  Misoprostol  Bilayer Floating 
Capsule 
Chawla et 
al,2004 
3  Glumetza 
GRTM 
Metformin HCL  Metformin HCL 
extended release 
tablet 
Bioavail oin 
north America; 
LG life 
sciences Korea 
 
 
 
 
 
 
 
Table 3: Some patents on gastroretentive drug delivery system 
US PATENT 
NUMBER 
YEAR  PATENT TITLE 
6,207,197  2001  Gastroretentive controlled release 
microsphere for improved drug delivery 
20060013876  2006  Novel floating dosage form 
200702817  2007  Gastroretentive sustain release dosage form 
2008020060  2008  Gastroretentive formulation and 
manufacturing process 
20090324694  2009  GRDDS comprising an extruded hydratable 
polymer 
20100286660  2010  Gastroretentive duodenal pill 
 
 
Figure 1: Interdigestive Motility 
 
Figure 2: Effervescent systems 
 
Figure 3: Drug release from swellable systems 
 
Figure 4: Shapes of unfoldable systems 
 
 
 